An effective protocol for pharmacological defatting of primary human hepatocytes which is non-toxic to cholangiocytes or intrahepatic endothelial cells
- PMID: 30044872
- PMCID: PMC6059478
- DOI: 10.1371/journal.pone.0201419
An effective protocol for pharmacological defatting of primary human hepatocytes which is non-toxic to cholangiocytes or intrahepatic endothelial cells
Abstract
Introduction: Pharmacological defatting of rat hepatocytes and hepatoma cell lines suggests that the same method could be used to ameliorate macrovesicular steatosis in moderate to severely fatty livers. However there is no data assessing the effects of those drugs on primary human liver cells. We aimed to determine the effectiveness of a pharmacological cocktail in reducing the in vitro lipid content of primary human hepatocytes (PHH). In addition we sought to determine the cytotoxicity of the cocktail towards non-parenchymal liver cells.
Methods: Steatosis was induced in PHH by supplementation with a combination of saturated and unsaturated free fatty acids. This was followed by addition of a defatting drug cocktail for up to 48 hours. The same experimental method was used with human intra-hepatic endothelial cells (HIEC) and human cholangiocytes. MTT assay was used to assess cell viability, triglyceride quantification and oil red O staining were used to determine intracellular lipids content whilst ketone bodies were measured in the supernatants following experimentation.
Results: Incubation of fat loaded PHH with the drugs over 48 hours reduced the intracellular lipid area by 54%, from 12.85% to 5.99% (p = 0.002) (percentage of total oil red O area), and intracellular triglyceride by 35%, from 28.24 to 18.30 nmol/million of cells (p<0.001). Total supernatant ketone bodies increased 1.4-fold over 48 hours in the defatted PHH compared with vehicle controls (p = 0.002). Moreover incubation with the drugs for 48 hours increased the viability of PHH by 11%, cholangiocytes by 25% whilst having no cytotoxic effects on HIEC.
Conclusion: These data demonstrate that pharmacological intervention can significantly decrease intracellular lipid content of PHH, increase fatty acids β-oxidation whilst being non-toxic to PHH, HIEC or cholangiocytes.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures





References
-
- Spitzer AL, Lao OB, Dick AA, Bakthavatsalam R, Halldorson JB, Yeh MM, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2010;16(7):874–84. Epub 2010/06/29. 10.1002/lt.22085 . - DOI - PubMed
-
- Nativ NI, Maguire TJ, Yarmush G, Brasaemle DL, Henry SD, Guarrera JV, et al. Liver defatting: an alternative approach to enable steatotic liver transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012;12(12):3176–83. Epub 2012/10/13. 10.1111/j.1600-6143.2012.04288.x ; PubMed Central PMCID: PMCPMC4047986. - DOI - PMC - PubMed
-
- Perez-Daga JA, Santoyo J, Suarez MA, Fernandez-Aguilar JA, Ramirez C, Rodriguez-Canete A, et al. Influence of degree of hepatic steatosis on graft function and postoperative complications of liver transplantation. Transplantation proceedings. 2006;38(8):2468–70. Epub 2006/11/14. 10.1016/j.transproceed.2006.08.077 . - DOI - PubMed
-
- de Graaf EL, Kench J, Dilworth P, Shackel NA, Strasser SI, Joseph D, et al. Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index. Journal of gastroenterology and hepatology. 2012;27(3):540–6. Epub 2011/07/23. 10.1111/j.1440-1746.2011.06844.x . - DOI - PubMed
-
- Nagrath D, Xu H, Tanimura Y, Zuo R, Berthiaume F, Avila M, et al. Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo. Metabolic engineering. 2009;11(4–5):274–83. Epub 2009/06/11. 10.1016/j.ymben.2009.05.005 ; PubMed Central PMCID: PMCPMC2814076. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources